Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-860-0045
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$143.89 million
Profitability
Miscellaneous
Employees64
OptionableOptionable
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.12. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.02 million. Concert Pharmaceuticals had a negative return on equity of 20.81% and a negative net margin of 392.62%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
4 Wall Street analysts have issued twelve-month price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $19.00 to $27.00. On average, they anticipate Concert Pharmaceuticals' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (1/3/2019)
- 2. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19." (8/2/2018)
Has Concert Pharmaceuticals been receiving favorable news coverage?
Press coverage about CNCE stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Wave Life Sciences (WVE), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI) and Tricida (TCDA).
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
- Ms. Nancy Stuart, Chief Operating Officer (Age 61)
- Dr. James V. Cassella, Chief Devel. Officer (Age 64)
- Mr. Marc A. Becker, Chief Financial Officer (Age 47)
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Steward Partners Investment Advisory LLC (0.25%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Nancy Stuart, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which major investors are buying Concert Pharmaceuticals stock?
CNCE stock was acquired by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Richard Aldrich and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $14.22.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $333.17 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.
What is Concert Pharmaceuticals' official website?
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
